CELF1 was reported to promote proliferation, migration, and invasion of CRC cells in vitro and in vivo through upregulating ETS2 and induced resistance to oxaliplatin (Wang et al., 2020). The gene discussed is ETS2; the disease is colorectal carcinoma.